

82. The pharmaceutical composition of claim 81, wherein the oral dosage form is a tablet or capsule.

83. The pharmaceutical composition of any of claims 79 to 82, further comprising a second therapeutic agent.

84. Use of a compound of any of claims 1 to 78 or the pharmaceutical composition of any of claims 79 to 83 in the manufacture of a medicament for ~~A method for~~ the treatment, prevention, or amelioration of one or more symptoms of a PI3K-mediated disorder, disease, or condition in a subject, ~~which comprises administering to the subject the compound of any of claims 1 to 78 or the pharmaceutical composition of any of claims 79 to 83.~~

85. The ~~method-use~~ of claim 84, ~~wherein~~wherein the PI3K-mediated disorder, disease, or condition is an inflammatory disease.

86. The ~~method-use~~ of claim 84 or 85, wherein the compound or the composition is to be administered in combination with a second therapeutic agent.

87. An *in vitro* method for modulating PI3K enzymatic activity, comprising contacting a PI3K enzyme with the compound of any of claims 1 to 78 or the pharmaceutical composition of any of claims 79 to 83.

88. The method of any of claims 84 to 87, wherein the PI3K is a wild type.

89. The method of any of claims 84 to 87, wherein the PI3K is a PI3K variant.

90. The method of any of claims 84 to 89, wherein the PI3K is a Class I PI3K.

91. The method of claim 90, wherein the PI3K is p110 γ .